← Back to patent-cliff list
SEP-4199
Tier C — Watch / tradeSEP-4199
Sunovion Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT7
Indications (approved)：Depression, Bipolar I disorder
Regional status
US
Phase III
2021-09-30
EU
Discontinued
2021-12-21
China
-
Japan
Phase III
2021-09-30
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SEP-4199?
Approved indications include: Depression, Bipolar I disorder.
When does the SEP-4199 patent expire?
No public expiry year is available for SEP-4199 yet; this page updates once verified.
How do I get a quote for SEP-4199 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06